FDA Releases Guidance on Delayed Ventricular Repolarization for Human Pharmaceuticals

Summary

The FDA has made available a guidance document outlining a nonclinical testing strategy to assess the potential of pharmaceuticals to delay ventricular repolarization, a condition that can increase the risk of arrhythmias.